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270a Monday, February 17, 2014between pH 10.5 and 5.5, while the solubility changes>100x. We infer that am-
yloid aggregation can start without significant conformational changes.
A significant part of the aggregation / organization of this extra cellular peptide
probably takes place in the in the lipid membrane. The affinity of the monomers
and oligomers for the lipid membrane, and the conformation that they adopt
there, remain open questions. We have recently found that Ab exhibits a strong
enhancement in its membrane-affinity as it transforms from monomers to olig-
omers (2). Using Fluorescence Correlation Spectroscopy, we have now estab-
lished a rapid and quantitative assay for this affinity. Further, using SERS of
lipid bilayer coated gold nano-particles, we are currently investigating the
conformation of Ab in lipid environments.
1. Nag, S., Sarkar, B., Bandyopadhyay, A., Sahoo, B., Sreenivasan, V. K.,
Kombrabail, M., Muralidharan, C., and Maiti, S. (2011) Nature of the
amyloid-beta monomer and the monomer-oligomer equilibrium. J Biol Chem
286, 13827-13833.
2. Sarkar, B., Das, A. K., and Maiti, S. (2013) Thermodynamically stable
amyloid-beta monomers have much lower membrane affinity than the small
oligomers. Front Physiol 4, 84.
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Protective effects of Transthyretin (TTR) ameliorate Alzheimer’s pathology in
mice models. This suggests a possible route for cellular defense mechanism
against toxic effects of protein misfolding and aggregation. This view is further
supported by the results from in vitro experiments showing direct interactions
between TTR and amyloid-b (Ab) peptides. However, the molecular mecha-
nism of the TTR-Ab interactions is currently unknown primarily due to hetero-
geneities associated with self-association of both TTR and Ab. Here we
investigate the mechanism of TTR-Ab interactions by examining the effects
of WT-human, a monomeric mutant and murine TTR on the kinetics of aggre-
gation of both Ab1-40 and Ab1-42. The three of forms of TTR differ in terms
of stability as tetramers or monomers, e.g., the WT-human and murine TTR are
primarily tetramers but the tetramers of murine TTR are more stable. To
monitor the aggregation of Ab but not of TTR we use a recently developed ag-
gregation assay based on the fluorescence quenching of tetramethyl rhodamine
(TMR)-labeled Ab. Our data indicate that all three TTR variants delay aggre-
gation of both Ab1-40 and Ab1-42. However, the effects are strongest for the
monomeric mutant and weakest for the murine TTR. Kinetic measurements of
fluorescence resonance energy transfer between native tryptophan residues of
TTR and the EDANS-labeled Ab indicate that binding of TTR is dependent
on the aggregation status of Ab with maximal binding occurring to larger ag-
gregates of Ab. Additionally, the modulatory effects of TTR are stronger on
Ab1-42 than on Ab1-40 consistent with the known higher oligomerization pro-
pensity for Ab1-42. Taken together our results indicate that the tetramers of
WT-human TTR dissociates to monomers to bind to the aggregation interme-
diates of Ab to subsequently slow down the growth of these intermediates.
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Epidemiologically, type-2 diabetes (T2D) doubles the risk for dementia linked
to cerebrovascular disease and/or Alzheimer’s disease (AD). We have recently
found that, in addition to plaques laden with Ab, the brain of demented T2D
patients also contains large deposits of amylin, a protein that makes up the
pancreatic amyloid in T2D. Deposition of amylin (or islet amyloid polypeptide;
IAPP) is promoted by hyperamylinemia, a key component of the metabolic
syndrome. In the brain, amylin was identified in the blood vessel wall, perivas-
cular space and tissue parenchyma. Moreover, we found amylin forming the
core protein deposit of some amyloid plaques or co-localized with Ab in com-
bined plaques suggesting an amylin-Ab pathology. Intriguingly, amylin depo-
sition was also detected in brain specimens from patients with AD without
clinically apparent diabetes. Amylin pathology in AD brain was similar to
that in brain samples from the T2D patients group, including buildup on blood
vessel walls and parenchyma. In contrast, brain specimens from age-matched
healthy humans show only sporadic amylin deposits in blood vessels and brainparenchyma. Cerebral deposition of amylin in non-diabetic AD patients may be
due to insulin resistance, which is common in aging.
To test the impact of hyperamylinemia on brain function, we use a rat model of
T2D expressing human amylin in the pancreas (the HIP rat). We found that the
infiltration of oligomerized amylin in cortical arteries induces lipid peroxida-
tion and triggers an inflammatory response. As a result, HIP rats display
changes in spontaneous activity and coordination. In contrast, rats matched
for weight, glucose and age, but expressing only the non-amyloidogenic rat
amylin, show no amylin accumulation and no behavioral changes.
In conclusion, hyperamylinemia promotes amylin deposition in the brain contrib-
uting to the development of cerebrovascular injury and neurological deficit.
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Tau is a non-motor microtubule-associated protein which functions to maintain
microtubule stability, primarily in the axons of neurons. The loss of this normal
function, along with the aggregation and deposition of tau as neurofibrillary
tangles, contributes to tau pathology in various neurodegenerative disorders,
including Alzheimer’s disease. Moreover, tau is reported to be an important
regulator to motor proteins in microtubule-based transport. While interactions
between tau and microtubules are of great interest, a detailed structural charac-
terization is lacking. Tau is intrinsically disordered, lacking stable secondary
and tertiary structure in solution, which makes it challenging to investigate
its structural features by conventional techniques. Here we use single molecule
Foster Resonance Energy Transfer (FRET) to probe the structure of tau bound
to microtubules in order to establish a structural framework for the mechanism
by which tau stabilizes microtubules. These measurements will not only pro-
vide insight into functional aspects of tau but also into the loss-of-function rele-
vant to disease.
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Biological processes offer several intriguing examples of directed self-
assembly into higher order structures that influence human health and well-
being. The aggregation of microtubule associating protein Tau, an intrinsically
disordered soluble protein that forms neurofibrillar tangles in cells in Alzheim-
er’s disease may be directed by the presence of hydrophobic templates. Using
various lipid monolayers and lipid-free surfaces we monitor the adsorption and
aggregation kinetics of Tau proteins to these model membranes. Monitoring the
surface tension change shows a two-step adsorption process followed by these
proteins. A novel microrheology and quartz crystal microbalance study shows
that the first step is dominated by the N-terminus of peptide, while the second
step is possibly due to an intermediate hair-pin structure. Our microrheology
data also show that the viscoelastic properties of these proteins is dominated
by the proteins propensity to aggregate.
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Tau is a microtubule binding protein that forms pathological aggregates in the
brain in Alzheimer’s disease and other tauopathies. Disease etiology is thought
to arise from loss of native interactions between tau and microtubules, as well
as from gain of toxicity tied to tau aggregation, although neither mechanism is
well-understood. We have investigated the link between function and disease
using disease-associated and designed disease-motivated mutants of tau. We
used fluorescence correlation spectroscopy (FCS) to measure tau binding to
free tubulin. We find that while the mutants bind stabilized microtubules
with comparable affinities, they demonstrate an increased affinity for tubulin
dimers. Morover, the mutant forms of tau are impaired in their ability to pro-
mote microtubule assembly. Using single
molecule FRET, we measure conforma-
tional changes in tau upon binding to
tubulin that provide a structural frame-
work for the observed altered affinity
and function. We propose a model that de-
scribes tau binding to tubulin dimers and a
